Scripps Research Institute: Study Confirms Long-term Benefit of Implant for Blinding Eye Disease
August 02, 2025
August 02, 2025
LA JOLLA, California, Aug. 2 (TNSjou) -- The Scripps Research Institute issued the following news:
* * *
Study confirms long-term benefit of implant for blinding eye disease
Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.
*
LA JOLLA, CA--For people with macular telangiectasia type 2 (MacTel), a . . .
* * *
Study confirms long-term benefit of implant for blinding eye disease
Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.
*
LA JOLLA, CA--For people with macular telangiectasia type 2 (MacTel), a . . .